Viral
Viral capability integrates rapid molecular and antigen diagnostics, genomic sequencing, viral culture, vaccine and antiviral development, and biosurveillance. In military settings it enables early outbreak detection, force health protection, accelerated countermeasure transition, and maintenance of readiness during delayed evacuation and austere operations.
Technical Challenges
Rapid identification and characterization of novel or highly mutated viral agents in far-forward conditions.
Differentiating active infection from prior exposure or vaccination (viral load vs serology) in polytrauma or immunomodulated patients.
Limited point-of-care assays that combine sensitivity, genomic breadth, and resistance profiling for antivirals.
Cold-chain, stability, and delivery constraints for vaccines, monoclonals, and biologics in austere environments.
Emerging Opportunities
Field-deployable sequencing and real-time genomic surveillance with low-power workflows.
Heat-stable, shelf-stable vaccines and therapeutics tailored for prolonged field care and delayed evacuation.
Integrated diagnostics that function with hemorrhage, polytrauma, co-infection, and antimicrobial resistance complications.
Faster pathways for transitioning validated viral countermeasures from lab to operational use under DoD timelines.
Current and Emerging Technologies in Viral
Point-of-care molecular and antigen diagnostics
Rapid PCR/RT-PCR, isothermal amplification (LAMP), and ultrasensitive antigen platforms enable near-patient detection to guide isolation and treatment in forward medical echelons.
Next-generation sequencing & genomic surveillance
Portable sequencers and cloud-enabled pipelines support variant detection, transmission mapping, and antiviral resistance monitoring critical for outbreak management.
mRNA, viral-vector and protein-subunit vaccines
Rapid-design vaccine platforms accelerate countermeasure generation; efforts focus on thermostability, dose-sparing, and rapid manufacturing for surge capacity.
Broad-spectrum antivirals and monoclonal antibodies
Host-targeted therapies, small-molecule antivirals and engineered monoclonals provide treatment options when diagnostics lag or for novel agents with unknown susceptibilities.
Biosensors, wearables and environmental surveillance
Continuous physiological and environmental monitoring, airborne and wastewater surveillance enable early warning systems that preserve force readiness and inform public health responses.
AI-enabled analytics and rapid regulatory frameworks
Machine learning for signal detection, triage, and variant impact prediction, combined with adaptive clinical trial and regulatory approaches, speeds field translation.
Importance to Military Medicine
Protect force readiness
Early detection and rapid countermeasures prevent outbreaks that degrade unit readiness and operational capability.
Enable prolonged and austere care
Thermostable vaccines, portable diagnostics, and field-suitable therapeutics are essential when evacuation is delayed or resources are limited.
Support combat casualty management
Viral co-infections and infection control issues complicate polytrauma care; fast diagnostics and targeted antivirals reduce morbidity and secondary complications.
Inform operational decision-making
Real-time surveillance data guide force protection, movement, and mission planning in dynamic biological threat environments.
Alignment with the MTEC Mission
Accelerates transition of viral diagnostics and countermeasures from prototype to operational use to shorten DoD timelines for fielding.
Supports DoD priorities for biosurveillance, force health protection, and resilience against emerging biological threats.
Enables dual-use outcomes that benefit civilian public health while meeting military operational requirements.
Dual-Use (Military + Civilian) Applications
Dual-use diagnostics reduce civilian outbreak impact while maintaining deployable capabilities for military operations.
Thermostable vaccines and scalable manufacturing support surge response for both humanitarian crises and combat-deployed forces.
Shared surveillance platforms and analytics inform public health and military command-and-control decision-making.
Platform technologies (mRNA, rapid assays, AI analytics) are adaptable for civilian therapeutics and commercial diagnostics.
Explore MTEC Members with Viral Capabilities
MTEC members bring multidisciplinary strengths—clinical virology, translational R&D, manufacturing scale-up, regulatory expertise, and field-validation networks—that accelerate operational impact. Explore member profiles to find collaborators with sequencing pipelines, vaccine platforms, point-of-care integration, and biosurveillance experience to address military and dual-use viral challenges.
137 Members with Viral capabilities.
The University of Texas System is a leading public university system in the United States, dedicated to improving lives through education, health care, and research. With over 256,000 students enrolled across 14 institutions, the UT System is committed to providing affordable access to higher education and producing a skilled workforce to drive Texas's economy.
Georgia Southern University is a vibrant institution with over 26,100 students across three campuses in Statesboro, Savannah, and Hinesville. The university offers 132 degree programs at the associate, bachelor’s, master’s, and doctorate levels, emphasizing student success, community impact, and research excellence. With a commitment to inclusivity and engagement, Georgia Southern fosters a supportive environment for diverse learners, including military-affiliated and adult students. The university is dedicated to transforming lives through education and community engagement, aligning its programs with regional needs. Additionally, Georgia Southern provides accelerated pathways for students to fast-track their master's degrees, enhancing educational opportunities. The university also emphasizes career readiness and public impact research, preparing students for successful careers and contributing to community development.
FiteBac Technology/FiteBac Pharma's K21 uniquely targets the underlying disease state, given that most diseases involve microbial-associated inflammation and mitochondrial dysfunction. FiteBac Technology innovations stem from the work of numerous international academic research scientists. FiteBac Pharma K21 is the blockbuster antimicrobial small molecule designed to modulate biological, immunological, and metabolic systems for treating a wide range of infectious and inflammatory diseases. This patented drug substance has demonstrated the ability to safely eliminate bacterial, fungal, and viral infections, enhance innate immunity, induce mitophagy while improving mitochondrial and cellular metabolism, accelerate wound healing, and even promote the development of zebrafish and chickens, leading to increased adult mass. Rigorous research from Dr. Bhupesh Prusty's laboratory and Dr Christopher Rongo's laboratory is focused on various aspects of mitochondrial remodeling and reprograming, as well as mitochondrial-to-nuclear signaling with K21.
STAT Therapeutics is focused on developing a drug- device combination for easy, rapid administration of intramuscular, life-saving medications by users in any setting, aiming to improve access and usability for acute emergency treatments such as pain, anaphylaxis, and seizures.
The University of Texas at San Antonio (UTSA) is dedicated to the advancement of knowledge through research, teaching, and community engagement. As a premier public research university, UTSA embraces multicultural traditions and serves as a catalyst for socioeconomic development, providing access to educational excellence and preparing citizen leaders for the global environment.
Auburn University Research & Economic Development is dedicated to advancing research and economic growth through a collaborative effort among its various colleges and departments. The organization focuses on fostering innovation, supporting faculty and student research, and facilitating partnerships with industry and government to address societal challenges and enhance the quality of life. Recent initiatives include the launch of the Team Science Series to promote interdisciplinary collaboration and the development of the Gulf Coast Engineering Research Station to address coastal environmental challenges.
Seek Labs is a biotechnology company headquartered in Salt Lake City, Utah, dedicated to advancing scientific discovery and delivering universal healthcare solutions. The company specializes in next-generation point-of-care molecular diagnostics and programmable CRISPR-based therapeutics, aiming to bridge the gap between disease outbreak and intervention. Powered by its proprietary AI discovery engine, BioSeeker™, Seek Labs is building a modular, full-stack system that enables rapid response to emerging pathogens, scalable precision treatments, and accessible diagnostics. The company is committed to global health innovation, sustainability, and community engagement, and is a proud member of Utah's BioHive life sciences ecosystem. Seek Labs' mission is to empower individuals with healthcare solutions tailored to their specific needs, revolutionizing the detection and treatment of diseases for both human and animal health.
The Institute for Integrative & Innovative Research (I³R) at the University of Arkansas is dedicated to pioneering solutions to wicked problems and societal challenges through convergence research. With a mission to advance research excellence and stimulate economic development, I³R focuses on deploying innovations at scale through collaboration across various sectors, including academia, industry, and government.
UTMB is dedicated to supporting research, education, and scholarly endeavors, with a focus on creating the future of healthcare through innovative research and community engagement.
Revolution Biomanufacturing Inc. (RBIx) is expanding beyond traditional CDMO Process/Analytical Development and Manufacturing services to pioneer distributed molecular manufacturing. A new class of digital biomanufacturing that enables the autonomous design, manufacture, quality verification, and deployment of Nucleic Acid therapeutics and molecular diagnostics at the point of need. By integrating AI-driven sequence optimization, enzymatic nucleic acid synthesis, Nanoparticle design and manufacturing (LNP & EV), closed-loop quality control, and field-deployable manufacturing platforms, RBIx is creating adaptive biological infrastructure capable of responding to emerging diseases, national security threats, and personalized medicine with unprecedented speed and flexibility.
The University of Chicago is a prestigious urban research university committed to rigorous inquiry and intellectual freedom. Founded in 1890, it has produced numerous Nobel laureates and is known for its transformative education and groundbreaking research across various fields. The university fosters an inclusive and diverse learning environment, encouraging participation from all community members.
Boston University is a major research institution committed to leading breakthroughs across various disciplines. The Office of Research supports and advances research excellence, fostering collaboration among researchers, industry partners, and government leaders to address significant societal challenges.
Island Pharmaceuticals Limited develops small molecule drugs for antiviral applications, with a principal focus on mosquito- and vector-borne infections such as dengue and Zika, and potential threats such as Marburg. The company emphasizes strategies to accelerate clinical timelines, harnessing compounds with established human safety profiles for rapid advancement through preclinical and clinical stages. It maintains active collaborative research and regulatory engagement, and is publicly listed on the Australian Securities Exchange.
ETC Innovation is a vertically integrated MedTech development company specializing in the design, development, and manufacturing of advanced wound dressing materials, antimicrobial substrates, and infection control products. The company brings together expertise in materials science, manufacturing processes, and regulatory compliance, offering solutions from concept through production for the medical industry. ETC Innovation operates a US-based facility supporting pilot to commercial-scale production, with a focus on custom materials for wound care and infection control. The company invests in R&D and holds equity in several early-stage medical device companies, and it provides proprietary material formulations, process development, and confidential research partnerships.
Baylor University is a preeminent Christian research university committed to addressing the world's most meaningful challenges through top-tier research and scholarship. Recognized as an R1 research institution, Baylor focuses on infusing its distinct Christian mission into its research initiatives, fostering a commitment to excellence and innovation.
Founded in 2016, Maxwell Biosciences is a preclinical stage biotechnology company focused on developing innovative therapeutics targeting viruses, bacteria, fungi, and biofilm formations. Utilizing a unique drug-discovery platform, the company aims to create affordable and effective health solutions to combat infectious diseases and enhance healthspan.
Moonrise Medical
Automated Portable Ultrasound for Rapid Vascular Assessment in Combat Casualty Care: Moonrise Medical Inc.
Moonrise Medical Inc. is developing an automated portable ultrasound system for rapid vascular assessment and real-time blood-flow monitoring in combat casualty care. The project is supported through MTEC Award No. 24-01-MPAI-149.
NIRSense
Rugged Physiological Monitoring for the Modern Warfighter: NIRSense
Under MTEC-21-10-NavyMultiTopic, NIRSense is advancing its tactical jet physiological monitoring technology for broader Navy applications. The project focuses on ruggedized, wireless physiological sensors that can provide reliable, real-time insight into warfighter health and performance in demanding operational environments.
Safi Biotherapeutics
Next-Generation Manufactured Red Blood Cells for Extended Battlefield Blood Supply: Safi Biotherapeutics
Safi Biotherapeutics is developing manufactured red blood cells (mRBCs) with extended shelf life to improve battlefield transfusion readiness and emergency trauma care.
Non-Invasive Glymphatic (GF) Monitoring and Recovery Optimization for Warfighter Cognitive Readiness
Applied Cognition is developing non-invasive glymphatic monitoring and recovery technologies to enhance warfighter cognitive readiness, resilience, and sleep recovery.